Table 2.
Clinical trials of rhGH development in recent years
| Name | Category | Sponsor | Current state of clinical trials |
|---|---|---|---|
| PEGylated somatropin | Prolonged half-life/PEGylation | GeneScience Pharmaceuticals Co., Ltd. | Phase III in 2011 |
| PEGylated-somatropin | Prolonged half-life/PEGylation | Xiamen Amoytop Biotech Co. Ltd. | Phase I in 2011 |
| MOD-4023 | Prolonged half-life/fused with carboxy-terminal peptide | Prolor Biotech, Inc. | Phase II in 2010 |
| VRS-317 | Prolonged half-life/fused with XTEN amino sequence | Versartis, Inc. | Phase I in 2011 |
| ACP-001 | Prolonged half-life | Ascendis Pharma A/S | Phase II in 2010 |
| ALTU-238 | Sustained-release/crystalline formulation | Altus Pharmaceuticals, Inc. | Phase II in 2006 |
| LB03002 | Sustained-release/sodium hyaluronate microparticles | LG Life Sciences | Phase IV in 2012 |
| NNC0195-0092 | Prolonged half-life/albumin conjugation | Novo Nordisk A/S | Phase I in 2012 |
| NNC126-0083 | Prolonged half-life/PEGylation | Novo Nordisk A/S | Phase II in 2009 |
| hGH-ViaDerm™ System | Transdermal | Teva Neuroscience, Inc. | Phase I in 2007 |
| PHA-794428 | Prolonged half-life/PEGylation | Pfizer, Inc. | Phase II in 2006 |
Note: Data source: http://clinicaltrials.gov.
Abbreviations: rhGH, recombinant human growth hormone; hGH, human growth hormone; PEG, polyethylene glycol.